Androgen ablation and blockade in the treatment of benign prostatic hyperplasia.
Antiandrogen therapy appears to produce a 30 to 40 per cent decrease in the volume of the hyperplastic prostate after 3 to 6 months of therapy (Table 5). Longer treatment may result in further prostatic regression, although this remains to be seen. Biopsy studies suggest that epithelial regression occurs to a much more significant degree than does stromal regression, but this finding may simply reflect the relatively longer turnover of the stromal cell population. The significant placebo effect of oral medication in patients with BPH makes interpretation of clinical symptomatology and uro-flow data difficult. Analysis of symptom improvement is further complicated by the relatively slow improvement of patients on antiandrogen therapy, in contrast to surgery, in which relief is immediate. In addition to limited stromal involution and inadequate treatment duration, other biologic factors may limit the clinical efficacy of antiandrogen therapy. Most importantly, prostatic involution may not necessarily decrease urethral resistance. In addition, obstruction-induced detrusor dysfunction may persist after relief of outflow obstruction in some patients, as it does after surgery. Incomplete antiandrogen action of the compounds, as well as compliance issues, may likewise limit efficacy. Although there are no data to suggest that the 5 alpha-reductase inhibitor finasteride will be more effective than other antiandrogen compounds in the treatment of BPH, preliminary studies suggest that it has less toxicity. If long-term studies validate a modest but significant clinical response rate and preservation of sexual function, then finasteride therapy may well be acceptable to a subgroup of men presenting with the symptoms of BPH.(ABSTRACT TRUNCATED AT 250 WORDS)
University of Texas Southwestern Medical Center, Dallas.
J D
JD
McConnell
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000736:Androstenes / Q000627:therapeutic use; D001378:Azasteroids / Q000627:therapeutic use; D018120:Finasteride; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000502:physiology; D008297:Male; D009919:Orchiectomy; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000601:surgery
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D000736:Androstenes; D001378:Azasteroids; D018120:Finasteride; D005485:Flutamide; D007986:Luteinizing Hormone